RecruitingPhase 1NCT05323487

Mechanisms of Diuretic Resistance in Heart Failure, Aim 1

Mechanisms of Diuretic Resistance in Heart Failure

Sponsor

Yale University

Enrollment

75 participants

Start Date

Jun 1, 2022

Study Type

INTERVENTIONAL

Conditions

Heart Failure

Summary

This study will employ a randomized order, double-blind, repeated measures dose ranging design. This design was chosen in order to generate multiple within-subject serial loop diuretic dose response exposures. The overall study schema will include 75 heart failure (HF) patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study explores why some heart failure patients stop responding to water pills (diuretics) over time — a problem called diuretic resistance — by looking at how the kidneys process salt and water differently in these patients. **You may be eligible if...** - You have heart failure with a history of worsening fluid retention despite water pills - You are 18 or older - You are stable enough to undergo study testing procedures - You are being managed at the participating hospital **You may NOT be eligible if...** - You are in acute heart failure crisis requiring emergency treatment - You have severe kidney failure - You are pregnant - You have contraindications to the study medications or procedures Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBumetanide Injection

Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.